Trial Profile
A Field Study for the Evaluation of AIGIV Clinical Benefit and Safety in the Treatment of Patients With Inhalational Anthrax in a Broad Exposure Event Scenario
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Anthrax immune globulin (Primary)
- Indications Anthrax
- Focus Therapeutic Use
- Sponsors Emergent BioSolutions
- 14 Feb 2024 Planned End Date changed from 1 Jul 2025 to 1 Jul 2026.
- 14 Feb 2024 Planned primary completion date changed from 1 Jul 2025 to 1 Jul 2026.
- 14 Feb 2024 Planned initiation date changed from 11 Feb 2024 to 11 Feb 2025.